Multi-Centre Gastroschisis Interventional Study Across Sub-Saharan Africa

Overview

This study is a multi-centre interventional study at seven tertiary paediatric surgery centres in Ghana, Zambia, Malawi and Tanzania aimed at reducing mortality from gastroschisis.

Full Title of Study: “Developing and Implementing an Interventional Bundle to Reduce Mortality From Gastroschisis in Low-Resource Settings”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Non-Randomized
    • Intervention Model: Single Group Assignment
    • Primary Purpose: Treatment
    • Masking: None (Open Label)
  • Study Primary Completion Date: November 8, 2020

Detailed Description

Background: Gastroschisis has a great disparity in outcomes globally with less than 4% mortality in high-income countries (HICs) and over 90% mortality in many tertiary paediatric surgery centres across sub-Saharan Africa (SSA), including the study centres. Low-technology, cost-effective, evidence-based interventions are available with the potential for improved outcomes in low-resource settings. Aim: To develop, implement and prospectively evaluate an interventional care bundle to reduce mortality from gastroschisis in seven tertiary paediatric surgery centres across SSA. Study Design: A hybrid type 2 effectiveness-implementation study design will be utilised, which focusses equally on the effectiveness of the intervention through analysing clinical outcomes and effectiveness of the implementation through analysis of service delivery and implementation outcomes. Methods: Using current literature an evidence-based, low-technology interventional care bundle has been developed with both pre-hospital and in-hospital components. During 2018 a systematic review, qualitative study and Delphi process will provide further evidence in order to optimise the interventional bundle and implementation strategy for use in low-resource environments. The interventional care bundle has core components, which will remain consistent across the seven sites, and adaptable components, which will be determined through in-country co-development meetings with all relevant members of the multi-disciplinary team. Across the seven study sites it is estimated that 180-289 patients will be included in the study, which has the potential to determine a difference in pre- and post-intervention mortality between 10-15%. Implementation will take place over a 4-week period at each of the study sites between April – December 2019. Pre- and post-interventional data will be collected on clinical, service delivery and implementation outcomes between September 2018 to October 2020 (2-years of patient recruitment at each site with a 30-day post primary intervention follow-up period). The primary clinical outcome will be all-cause, in-hospital mortality. Secondary outcomes include the occurrence of a major complication, length of hospital stay and time to full enteral feeds. Service delivery outcomes include time to hospital and primary intervention and adherence to the pre-hospital and in-hospital management protocols. Implementation outcomes will include acceptability, adoption, appropriateness, feasibility, fidelity, coverage, cost and sustainability. Expected Results: Pre- and post-intervention clinical outcomes will be compared using Chi-squared analysis, unpaired t-test and/ or Mann-Whitney test. Time-series analysis will be undertaken using Statistical Process Control to identify significant trends and shifts in outcome overtime. Multivariate logistic regression analysis will be used to identify both clinical and implementation factors affecting outcome with adjustment for confounders. P<0.05 will be deemed significant. Outcome: This will be the first multi-centre interventional study to the investigator's knowledge aimed at reducing mortality from gastroschisis in low-resource settings. If successful, detailed evaluation of both the clinical and implementation components of the study will allow sustainability in the study sites and further scale-up.

Interventions

  • Combination Product: Pre-hospital interventional care bundle
    • The interventional care bundle will include pre-hospital and in-hospital components and core and adaptable components. All seven centres will implement the core pre-hospital and in-hospital components. Implementation of the adaptable components will be decided by the local team to optimise the interventional care bundle to the local environment. Pre-hospital core components: 1) covering the bowel in clear plastic, 2) administering intravenous fluids, 3) keeping the neonate warm, 4) transferring to a study centre as soon as possible. This will be implemented as a pre-hospital gastroschisis care protocol to district and secondary level hospitals who refer patients with gastroschisis to the study centres. Pre-hospital adaptable components: 1) the strategy for disseminating the pre-hospital gastroschisis care protocol.
  • Combination Product: In-hospital interventional care bundle
    • In-hospital core components: 1) use of a standardised care protocol, 2) neonatal resuscitation and ward care including intravenous access, intravenous fluids, maintenance of normothermia, appropriate antibiotics, regular monitoring and infection control, 3) gastroschisis reduction and sutureless closure using a preformed silo and avoidance of neonatal anaesthesia and surgery, 4) early establishment of breastfeeding and an enhanced enteral feeding programme. In-hospital adaptable components: 1) administration of parenteral nutrition for neonates who have survived for 1-week in hospital, 2) maternal involvement in monitoring and basic management, 3) management of neonates with gastroschisis on the neonatal intensive care unit if available.

Arms, Groups and Cohorts

  • No Intervention: Pre-intervention
    • Patients presenting with simple gastroschisis during the pre-intervention phase will receive the current care provided by the study sites (no intervention).
  • Active Comparator: Post-intervention
    • Patients presenting with simple gastroschisis during the post-implementation phase will receive the interventional care bundle if consent for participation is provided.

Clinical Trial Outcome Measures

Primary Measures

  • All-cause, in-hospital mortality
    • Time Frame: Mortality whilst in hospital during primary admission, up to 30-days post-intervention or 30-days from admission for those not receiving an intervention and still in hospital.
    • Percentage of patients with gastroschisis dying in hospital during their primary admission.

Secondary Measures

  • Percentage of patients experiencing a major complication within 30-days of primary intervention*
    • Time Frame: Within 30-days of primary intervention.
    • Major complications are secondary bowel ischaemia, necrosis or perforation requiring resection**, abdominal compartment syndrome*** or need for further unplanned surgical intervention. *Defined as the first bowel intervention the neonate received including silo application or primary closure. **Defined as bowel necrosis or perforation that was not present prior to primary intervention and hence occurred after primary intervention. ***Defined as respiratory insufficiency secondary to compromised tidal volumes, decreased urine output by falling renal perfusion (<1ml/kg/hr) and any other organ dysfunction caused by increased intra-abdominal pressure (based on clinical judgement – the pressure does not have to be measured to fulfil the criteria).
  • Length of hospital stay amongst survivors
    • Time Frame: Up to a maximum of 30-days following primary intervention.
    • In days.
  • Time to full enteral feeds
    • Time Frame: Up to a maximum of 30-days following primary intervention.
    • In days
  • Need for ventilation
    • Time Frame: Up to a maximum of 30-days following primary intervention.
    • Yes/ no. This does not include ventilation given during anaesthesia for intervention(s).
  • Duration of ventilation
    • Time Frame: Up to a maximum of 30-days following primary intervention.
    • IN days. All ventilation types included.

Participating in This Clinical Trial

Inclusion Criteria

  • all neonates presenting primarily to the study centre with simple gastroschisis regardless of weight, gestational age or co-morbidities. Exclusion Criteria:

  • all neonates with 'complex gastroschisis' requiring surgical intervention for bowel necrosis, perforation, atresia or other reason.

Gender Eligibility: All

Minimum Age: N/A

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • King’s College London
  • Collaborator
    • Korle-Bu Teaching Hospital, Accra, Ghana
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • Naomi J Wright, MBChB BSc MRCS DCH MSc, Principal Investigator, King’s College London
  • Overall Contact(s)
    • Naomi J Wright, MBChB BSc MRCS DCH MSc, 0044 7824468954, paedsurg.research@gmail.com

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.